Guerbet : Unexpected replacement of the CEO - 2023 guidance suspended - Downward revision to our estimates, target price and recommendation
>Yves L’Epine, CEO since 2011, replaced – Road map adjusted - In a press release issued yesterday evening, we learned that Guerbet’s board of directors:i/ has appointed David Hale to the post of CEO as of 1 January 2020, replacing Yves L’Epine (CEO since end-2011); ii/ confirmed the group’s strategic ambition - expressed via the GEAR 2023 plan with development in the interventional radiology and digital segments - but indicated that an updated plan would be ...Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.